Leukocyte adhesion in the microvasculature influences blood rheology and plays a key role in vaso-occlusive (VOC) manifestations of sickle cell disease (SCD). Notably, polymorphonuclear neutrophils (PMNs) can capture circulating sickle red blood cells (sRBCs) in inflamed venules leading to critical reduction in blood flow and VOC. Recent studies have suggested that Eselectin expression by endothelial cells plays a key role by sending activating signals leading to the activation of Mac-1 at the leading edge of PMNs thereby allowing RBC capture. Thus, the inhibition of E-selectin may represent a valuable target in this disease. Here, we have tested the biological properties of a novel synthetic pan-selectin inhibitor, GMI-1070, using in vitro assays and in a humanized model of sickle cell vaso-occlusion analyzed by intravital microcopy.
Introduction
Sickle cell disease (SCD), one of the most common inherited blood disorders in the United States 1 , results from a single amino acid substitution in the gene encoding the β -globin subunit (HbβS) 2 . HbβS polymerizes in deoxygenation, producing less deformable sickle red blood cells (sRBCs) that can obstruct blood vessels 3 . Recurrent vasoocclusive (VOC) episodes cause irreversible organ damage and contribute to morbidity and mortality in sickle cell disease patients due to acute pain crises, chronic inflammation, and ischemic end-organ damage, such as pulmonary hypertension, renal failure, and cerebrovascular injury 4 . Although the molecular basis of SCD has been well characterized, the complex cellular and molecular mechanisms underlying vasoocclusion have not been fully elucidated.
Recent studies have suggested that VOC is a complex cascade involving multiple blood cells, adhesion and signaling molecules 5 . Intravital microscopy analyses in a SCD mouse model expressing exclusively human globin genes 6 indicate that sRBCs interact primarily with adherent leukocytes (WBCs) in postcapillary and collecting venules of cremasteric muscle, and leading to vascular obstruction 7 . The key role for leukocyte adhesion in sickle cell vascular occlusions has been suggested by the amelioration of flow abnormalities in sickle transgenic mice by anti-inflammatory therapies directed at NF-kappaB activation, reactive oxygen species (ROS), or endothelial adhesion molecules such as VCAM-1, ICAM-1, or the selectins [7] [8] [9] .
The selectins comprise a family of three members mediating adhesion events between blood cells and the endothelium. L-selectin is constitutively expressed on leukocytes and mediate lymphocyte recruitment in lymph nodes and secondary tethers between leukocytes in activated venules. Endothelial cells express two selectins, P-selectin which is stored in WeibelPalade bodies and can be rapidly translocated to the cell surface upon stimulation, and Eselectin whose expression is induced by inflammatory cytokines such as TNF-α or IL-1β 10 .
Selectins mediate leukocyte rolling along on the endothelium, allowing leukocytes to rapidly decelerate and come into close contact with chemokines that will induce firm adhesion. While mice lacking single selectin genes have relatively mild deficits in leukocyte recruitment, animals deficient in both P-and E-selectins exhibit severe defects in leukocyte adhesion 11, 12 , and are protected from VOC 7 . Most studies evaluating the selectin functions in various animal models have confirmed their overlapping functions, suggesting that the greatest potential for therapy may involve the inhibition of more than one selectin 13 . However, recent studies of the individual
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From function of single selectins in a mouse model of SCD have revealed a key role for E-selectin, but not P-selectin, in sending activating signals leading to the upregulation of the β2 integrin Mac-1 specifically at the leading edge of crawling neutrophils in inflamed venules 14 All three selectins bind to sialylated and fucosylated moieties presented by glycoprotein or glycolipid ligands.
The involvement of the selectins in numerous disease states has spurred research into the development and rational design of drugs that target selectins and their ligands. By promoting the extravasation and migration of cells out of the bloodstream, the selectins have been identified as drug targets for inflammatory diseases 15 and for metastasis of cancer cells 16, 17 . Past attempts to impact successfully these diseases with selectin antagonists have suffered from the construction of molecules with low affinity, inadequate specificity and/or poor drug-like properties such as pharmacokinetics and stability [18] [19] [20] .
Here, we have evaluated the biological effects of GMI-1070, novel small molecule glycomimetic pan-selectin antagonist, in leukocyte-endothelial interactions in vivo and VOC in a sickle cell mouse model.
Material and Methods

Animals
Bone marrow nucleated cells from Berkeley sickle cell mice 21 were transplanted into lethally irradiated C57BL/6 animals to generate age-and gender-matched genetically identical cohorts of SCD mice. Fully chimeric male sickle cell mice (expressing >97% human globin, including βS) were subjected to intravital microscopy 3-5 months after bone marrow transplantation 7 .
ELISA binding protocol
The 
In vitro flow assay protocol
To model selectin mediated cell adhesion in vitro under hydrodynamic shear force, a flow chamber was employed and adhesion events were recorded under low light microscopy and analyzed by digital image analysis. Briefly, the parallel plate flow chamber with a silicon rubber For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From diameter, and is expressed as 10 -6 µL / s. Blood samples taken immediately after recording, through a cardiac puncture, were used to determine leukocyte counts using a hemocytometer.
Image analyses
All analyses were made using playback assessment of videotapes as previously described 7, 14, 22 . Briefly, rolling WBCs were defined as those moving at a velocity less than that of free-flowing erythrocytes in a given vessel and counted over 1-min intervals per venule.
Adherent WBCs were defined as those remaining stationary for at least 30 s over a 100 µm 
Statistical analyses
All data are shown as mean ± SEM. Parametric data were analyzed using ANOVA. Statistical significance for non-parametric distributions (RBC-WBC interactions) was assessed using the Mann-Whitney test. A value of p less than 0.05 was deemed significant.
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RESULTS
Generation and structure of GMI-1070
The selectin antagonist GMI-1070 was designed based on the bioactive conformation of sLe x in the carbohydrate binding domain of E-selectin as determined by NMR techniques 23, 24 .
Structural requirements for binding L-and P-selectins were also incorporated. The full synthetic scheme and molecular properties of GMI-1070 will be published elsewhere. The chemical structure of GMI-1070 is shown in Figure 2 .
GMI-1070 antagonizes all three selectins
The ability of GMI-1070 to inhibit binding to E-, P-, and L-selectins was evaluated using ELISA in which selectin chimeras were immobilized on microtiter plates and binding to sLe a or sLe x was determined. We found that the concentration of GMI-1070 required to inhibit binding by 50% (IC 50 ) was 4.3 µM for E-selectin, much lower than P-selectin (423 µM) or L-selectin (337 µM), suggesting that although GMI-1070 inhibits binding to all three selectins, its activity is greatest toward E-selectin. To investigate further this issue, we assessed the effect of GMI-1070 on selectin mediated cell adhesion in vitro using a parallel plate flow chamber. Confluent HUVEC monolayers were stimulated with TNF-α to induce the expression of E-selectin or IL-4
and histamine to upregulate P-selectin expression on the cell surface. PMNs were perfused through the chamber containing GMI-1070 under a shear stress of 0.9 dynes / cm 2 . Consistent with the ELISA findings, GMI-1070 inhibited the interactions of PMNs more effectively when Eselectin was induced on HUVEC as compared with P-selectin ( Figure 3 ).
GMI-1070 alters in vivo leukocyte rolling and recruitment
Preclinical studies on dosing and pharmacokinetics have established that GMI-1070 administered intravenously, has a serum half-life of 1.25 h in mice and 7. (Table 1) . Leukocytes rolling, adhesion and RBC interaction with adherent leukocytes were monitored and analyzed in the 60 min interval between 90 and 150 min after the inflammatory challenge. Leukocyte rolling was assessed as leukocyte rolling flux fraction, defined as the number of rolling leukocytes divided by the total number of leukocytes passing through the same vessel. Under inflammatory condition induced by combined surgical exteriorization of the cremaster muscle and exposure to TNF-α, rolling flux fraction was ~4.6% in PBS-treated SCD mice. Virtually all rolling during this time interval was mediated by P-and E-selectins since it was completely ablated by co-injection of anti-P-selectin and anti-E-selectin antibodies. Unexpectedly, the rolling fraction was increased to 11% in GMI-1070-treated mice. (Figure 4A ; ***P<0.0001). The increased rolling fraction is reminiscent of experiments in which E-selectin is inactivated 25 , and confirms the in vitro studies described in the previous section, suggesting that GMI-1070 largely antagonizes Eselectin in vivo. The changes in rolling fractions were not due to alterations in leukocyte counts because similar conclusions can be drawn if the results are expressed as absolute numbers of rolling leukocytes per minute (10.9 ± 1.4 for PBS control; 41.6 ± 3.5 for GMI-1070 and 0.3 ± 0.1 for the group anti-P-and E-selectin; all groups P < 0.01 compared to PBS). By contrast, the average number of WBCs adherent to endothelium was reduced by approximately 53% in GMI-1070-treated SCD mice compared with PBS-treated SCD control (Figure 4B -C; ***P<0.0001), suggesting significant blockade of P-selectin. Leukocyte adhesion was markedly reduced (by ~97%) when endothelial selectins were blocked using antibodies ( Figure 4B-C) .
GMI-1070 dramatically increases leukocyte rolling velocities
In order to understand further the mechanisms, we characterized leukocyte behavior in more detail by evaluating the velocity of leukocyte rolling in 193 leukocytes from 42 venules of 6 PBS-treated SCD mice and 481 leukocytes from 51 venules of 6 GMI-1070-treated SCD mice.
Leukocytes in PBS-treated SCD mice rolled at an average velocity of 20.9 ± 1.1 µm/sec, ranging from 0.3 to 86 µm / sec ( Figure 5A ). In contrast, average leukocyte rolling velocity in SCD mice treated with GMI-1070 was significantly increased at 37.8 ± 1.2 µm / sec, ranging from 2. Figure 5D ). The dramatic effect of GMI-1070 on leukocyte rolling velocities is consistent with efficient in vivo blockade of E-selectin function.
GMI-1070 inhibits RBC interactions with WBCs
Our recent studies have revealed that E-selectin-induced neutrophil activation was critical to enable their capture of circulating RBCs 14 . To assess the effect of GMI-1070 on sickle cell adhesion, we quantified the interactions between circulating RBCs and adherent WBCs in venules recorded between 90 and 150 minutes. We found that the administration of GMI-1070 markedly reduced the number of RBCs interacting per adherent WBC (~93% reduction; Figure   6A ; P < 0.001). These data suggest that a selectin antagonist can affect the capture of RBCs even when adherent leukocytes are already recruited.
During intravital microscopy studies, hemodynamic parameters were measured using an optical velocimeter and leukocyte behavior were recorded and then analyzed. The mean centerline RBC velocity (V RBC ) in mice treated with GMI-1070-treated or P-and E-selectin antibodies were almost equal and were significantly higher than that in PBS-treated control mice by near to 2-fold (P < 0.001 Table 1 ). This difference was not attributable to venular size because the average venular diameter (~21 µm) was nearly identical among the 3 groups (Table 1) . As a result, the wall shear rates (γ ) in GMI-1070 and anti-P-and E-selectins-treated animals were almost 2-fold greater than PBS-treated control. Owing to reduced leukocyte recruitment and sRBC interactions in the microvasculature, the average blood flow rates were dramatically improved in mice treated with GMI-1070 or anti-P-and E-selectins, compared with the PBS control group ( Figure 6B ; ***P<0.0001).
GMI-1070 administration inhibits leukocyte adhesion and sickle RBC interactions after the inflammatory trigger
To evaluate the potential therapeutic effects of GMI-1070 in the painful sickle crisis, we 
GMI-1070 reverses sickle cell crisis by improving blood flow and survival of SCD mice
Administration of GMI-1070 110 min after the inflammatory stimuli increased the mean V RBC by almost 2-fold compared to PBS-treated controls (P <0.0001; Table 2 ). This difference was also not attributable to venular size because the average venular diameter was nearly identical between 2 groups ( Table 2 ). The calculated mean blood flow rate, which can be regarded as a surrogate measure for vaso-occlusion, was more than 2-fold higher in GMI-1070-treated mice than control animals ( Figure 8A ; P <0.0001). After the end of the recording period, mice were monitored for up to 11 h after the injection of TNF-α to assess the effect of the GMI-1070 therapy on mortality. Kaplan-Meier survival curves revealed a dramatic improvement in survival of GMI-1070-treated compared with PBS control SCD mice ( Figure 8B ; P=0.007, logrank test). The median survival in PBS-treated control was at least 4 h shorter than GMI-1070-treated SCD mice (5 h versus 9.7 h, respectively). Taken together, these results strongly suggest that GMI-1070 therapy may be beneficial in SCD during acute crisis.
DISCUSSION
These studies provide the proof-of-principle of the treatment of sickle cell crises using selectin inhibitors. Our data support the notion that vaso-occlusion in SCD is not a fixed irreversible event but a highly dynamic process that potentially could be reversed by targeted For example, both of these previous attempts produced molecules with relatively weak inhibitory activity for E-selectin (IC 50 > 500 μM). The structure of GMI-1070 was rationally designed based on the bioactive conformation of sLe x in the binding site of E-selectin as determined empirically by NMR methods rather than molecular modeling. This approach led to potent E-selectin inhibitory activity (IC 50 = 4.3 μM) along with good drug-like properties such as low toxicity, metabolic stability, and adequate half-life profile.
Although all three selectins bind to sLe x , the efficiency of interactions with P-selectin and L-selectin is greatly enhanced by additional interactions with negatively charged structures. For example, P-selectin glycoprotein ligand-1 (PSGL-1) harbors sulfated N-terminal tyrosine residues 26 , whereas putative L-selectin ligands have sulfated glycoconjugates 27 . Since soluble sLe x display mild selectin antagonistic activity in vivo 28 , and disappointing results in clinical trials 29 , GMI-1070 was rationally designed to contain both a more potent sLe x mimetic with an extended sulfated domain) to accommodate the binding requirements of P-and L-selectins and confer drug-like properties to the molecule 23, 30, 31 .
GMI-1070 is a pan-selectin inhibitor by design appears to largely act as an E-selectin antagonist in vivo with partial inhibition of P-selectin at these doses, which is consistent with solid-phase in vitro assays and the results using a parallel plate flow chamber where the activity against E-selectin predominates. This conclusion from the intravital microscopy analyses is supported by the absence of any reduction in leukocyte rolling and mild effect on leukocyte adhesion. In fact, the leukocyte rolling fraction and rolling velocities were both significantly increased shortly after the administration of GMI-1070, a hallmark of E-selectin inhibition.
For
Interestingly, the partial overall blockade of leukocyte adhesion by GMI-1070 appeared to be as efficient in protecting against VOC as the administration of two antibodies against either endothelial selectins. These data are consistent with our recent studies where we have described a major role of E-selectin in sending activating signals into neutrophils that lead to the regional activation of Mac-1 at the leading edge of neutrophils, thereby allowing RBC captures, reduction in blood flow and vasoocclusion 14 . Indeed, GMI-1070 dramatically inhibited RBC-WBC interactions, improved blood flow and survival of SCD mice, emphasizing a major role for E-selectin in these activities. In further support of these findings, the levels of circulating Eselectin in SCD patients was shown to correlate positively with the rate of mortality over a 4 year period 32 .
In inflamed venules, leukocyte recruitment is an extremely dynamic process where many adherent leukocytes continuously crawl to survey the venular endothelium while others detach to return in the circulation. Extravasated leukocytes account for a relatively minor subset of leukocytes that have adhered. Even after administration long after the inflammatory challenge was initiated, GMI-1070 rapidly reduced the number of adherent leukocytes and also rapidly inhibited RBC-WBC interactions. These effects on leukocyte behavior are remarkably similar to those previously reported with intravenous gammaglobulin administration 22 , suggesting parallel mechanisms between the two drugs. The similar effects observed in the two protocols highlight dynamic nature and potential reversibility of leukocyte adhesion and activation following targeted intervention, at least under the conditions studied herein.
It is important to mention the differences between this mouse model of SCD and the human disease. This mouse model of VOC is generally much more severe than the human disease in that it can lead to the death of most animals in several hours, in contrast with human sickle cell crises that are usually brought up over hours to days and are usually not lethal.
However, we would argue that disease reversibility in face of such a severe model bodes well for potential clinical relevance of a specific intervention. A phase I clinical trial has recently indicated that GMI-1070 has a good safety profile with a serum half-life of seven to eight hours.
Metabolism is also minimal since over 90% of the drug is excreted intact and no serious adverse events due to toxicity were observed (J.L.M., unpublished data). The dramatic effects of GMI-1070, including the significant protection from death even when the drug is administered long after the inflammatory trigger, warrant further study in a clinical trial to treat acute VOC. For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Figure 2 
